Drug Trial Radar · NCT04116541
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
455
Planned (sponsor's estimate)
Start
Jan 28, 2020
Primary completion
Oct 2026
Study completion Oct 2027
Sponsor
- Lead sponsor
- Centre Leon BerardAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts of treatment. Patients will be assigned to a treatment cohort based on molecular alterations/characteristics detected on tumor sample from primary tumor or metastatic lesion. In this protocol, several MTTs treatment cohorts are planned. This study is designed with the flexibility to open new MTTs treatment cohorts and to close existing MTTs treatment cohorts that demonstrate no clinical benefit. Each treatment cohort will be driven separately even though procedures, quality control and reporting, will be common. The protocol will be amended in order to include new treatments or combinations that emerge as being of interest for patients with advanced/metastatic cancers. All eligible patients will receive study drugs as long as patient experiences clinical benefit in the opinion of the investigator, or until unacceptable toxicity, or until symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status, or withdrawal of consent. Patients will be permitted to continue study treatment after progressive disease according to RECIST v1.1 if they meet all of the following criteria and following validation of the Sponsor: * Evidence of clinical benefit as assessed by the investigators, * Absence of symptoms and signs (including worsening of laboratory values; e.g., new or worsening hypercalcemia) that indicate unequivocal progression of disease, * No decline in ECOG Performance Status (PS) that can be attributed to disease progression.
Conditions
- Malignant Solid Tumor
Interventions
HDM201Drug
HDM201 120mg, Every 3 weeks, Per os
RibociclibDrug
Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
CabozantinibDrug
Cabozantinib, 60 mg /day, continuous, Per os
AlectinibDrug
Alectinib, 600mg twice daily, Per os
RegorafenibDrug
Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
TrametinibDrug
Trametinib 2 mg/day, continuous, Per os
DabrafenibDrug
Dabrafenib 150 mg twice daily, Per os
AvapritinibDrug
300 mg/day,continuous, Per os
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free rate after 3 months (12 weeks) of treatmentTime frame: 3 months (12 weeks)
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
INSTITUT DE CANCEROLOGIE DE L'OUEST Pays de Loire
Angers, France · Not yet recruiting
Institut Bergonié
Bordeaux, France · Recruiting
Centre François Baclesse
Caen, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Institut Paoli Calmettes
Marseille, France · Recruiting
Centre Antoine LACASSAGNE
Nice, France · Recruiting
Institut Curie
Paris, France · Not yet recruiting
Centre Henri Becquerel
Rouen, France · Not yet recruiting
Centre Paul Strauss
Strasbourg, France · Recruiting
Institut de Cancérologie de Strasbourg
Strasbourg, France · Terminated
CHU Strasbourg - Hôpital de Hautepierre
Strasbourg, France · Recruiting
Institut Claudius Regaud
Toulouse, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.